Arvinas logo

PROTAC® BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors

James D. Winkler

March 4, 2016
14th International Congress on Targeted Anticancer Therapies (TAT)
Skip to content